{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ALNY","limit":50},"count":50,"signals":[{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"and updating our peer group for compensation purposes; reviewing and discussing our compensation policies and programs and assessing whether such policies and programs are reasonably likely to have a material adverse effect on the company; approving and overseeing our policy for clawback, or recoupment, of incentive compensation; establishing, amending and overseeing compliance with our stock ownership guidelines for ou","filed_date":"2026-04-06","accession":"0001628280-26-023923","full_text":"https://origin.rootz.global/static/filing/0001628280-26-023923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"rve as a ClassI director for a term ending in 2029, or until a successor has been duly elected andqualified; | | | | | | | | | 2 | To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | | | | | | | | 3 | To ratify the appointme","filed_date":"2026-04-06","accession":"0001628280-26-023923","full_text":"https://origin.rootz.global/static/filing/0001628280-26-023923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":88,"context":"member cost-sharing) have been the subject of regulatory action and litigation. Actions that restrict or limit the impact of such financial assistance could reduce demand for our products and have a material adverse effect on our sales, business, and financial condition. In the U.S., healthcare and pharmaceutical pricing have been the subject of reform efforts and the federal government continues to propose and impleme","filed_date":"2026-02-12","accession":"0001628280-26-007497","full_text":"https://origin.rootz.global/static/filing/0001628280-26-007497.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"tion. Any failure to complete any stage of the development of any potential products in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2025-10-30","accession":"0001628280-25-047345","full_text":"https://origin.rootz.global/static/filing/0001628280-25-047345.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":50,"context":"ection 5.03. |  |  Governmental Authorization; Other Consents |  |  |  103 |  | | |  |  |  Section 5.04. |  |  Binding Effect |  |  |  104 |  | | |  |  |  Section 5.05. |  |  Financial Statements; No Material Adverse Effect |  |  |  104 |  | | |  |  |  Section 5.06. |  |  Litigation |  |  |  104 |  | | |  |  |  Section 5.07. |  |  Ownership of Property; Liens |  |  |  104 |  | | |  |  |  Section 5.08. |  |  Environmenta","filed_date":"2025-10-03","accession":"0001193125-25-230201","full_text":"https://origin.rootz.global/static/filing/0001193125-25-230201.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":39,"context":"tion. Any failure to complete any stage of the development of any potential products in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2025-07-31","accession":"0001178670-25-000090","full_text":"https://origin.rootz.global/static/filing/0001178670-25-000090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":38,"context":"tion. Any failure to complete any stage of the development of any potential products in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2025-05-01","accession":"0001178670-25-000052","full_text":"https://origin.rootz.global/static/filing/0001178670-25-000052.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"and updating our peer group for compensation purposes; reviewing and discussing our compensation policies and programs and assessing whether such policies and programs are reasonably likely to have a material adverse effect on the company; approving and overseeing our policy for clawback, or recoupment, of incentive compensation; establishing, amending and overseeing compliance with our stock ownership guidelines for ou","filed_date":"2025-03-24","accession":"0001178670-25-000040","full_text":"https://origin.rootz.global/static/filing/0001178670-25-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":"n, to, among other things, increase the number of shares authorized for issuance thereunder by 7,000,000 shares; | | | | | | | 4 | To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | | | | | | 5 | To ratify the appointment o","filed_date":"2025-03-24","accession":"0001178670-25-000040","full_text":"https://origin.rootz.global/static/filing/0001178670-25-000040.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":90,"context":"tion, could restrict or otherwise negatively affect these co-pay coupon programs and patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on pharmaceutical manufacturers sales, business, and financial condition. At the state level, governments have enacted and continue to consider legislation and regulations focused on pharmaceutical p","filed_date":"2025-02-13","accession":"0001178670-25-000026","full_text":"https://origin.rootz.global/static/filing/0001178670-25-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2024-10-31","accession":"0001178670-24-000053","full_text":"https://origin.rootz.global/static/filing/0001178670-24-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2024-08-01","accession":"0001178670-24-000041","full_text":"https://origin.rootz.global/static/filing/0001178670-24-000041.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":33,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2024-05-02","accession":"0001178670-24-000023","full_text":"https://origin.rootz.global/static/filing/0001178670-24-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":13,"context":"peer group for compensation purposes; | | |  |  |  |  reviewing and discussing our compensation policies and programs and assessing whether such policies and programs are reasonably likely to have a material adverse effect on the company; | | |  |  |  |  reviewing and discussing annually with management our Compensation Discussion and Analysis, which is included beginning on page 49 of this proxy statement; | | |  |  |","filed_date":"2024-04-01","accession":"0001193125-24-083454","full_text":"https://origin.rootz.global/static/filing/0001193125-24-083454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"ch to serve as a ClassII director for a term ending in 2027, or until a successor has been duly elected and qualified; | | |  |  2.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | |  |  3.To ratify the appointment of Pric","filed_date":"2024-04-01","accession":"0001193125-24-083454","full_text":"https://origin.rootz.global/static/filing/0001193125-24-083454.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"nt for the treatment of hemophilia A or B, with or without inhibitors, and an NDA submission with the FDA is expected in 2024Early-Stage and Pre-Clinical PipelineZilebesiran HypertensionCompleted enrollment in the KARDIA-2 Phase 2 study, evaluating the safety and efficacy of zilebesiran in patients with uncontrolled hypertension when added on top of another antihypertensive medicationReported positiv","filed_date":"2024-02-15","accession":"0001178670-24-000008","full_text":"https://origin.rootz.global/static/filing/0001178670-24-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":89,"context":"ction could restrict or otherwise negatively affect these co-pay coupon programs and patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on pharmaceutical manufacturers sales, business, and financial condition. At the state level, governments have and continue to consider legislation and regulations designed to control pharmaceutical","filed_date":"2024-02-15","accession":"0001178670-24-000008","full_text":"https://origin.rootz.global/static/filing/0001178670-24-000008.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ated to the HELIOS-B Phase 3 clinical trial. In November 2021, Blackstone Life Sciences opted in to Phase 2 clinical trial funding of zilebesiran, committing to fund, upon meeting certain patient enrollment thresholds, up to $26.0million. Furthermore, Blackstone Life Sciences has the right, but is not obligated, to fund up to $54.0million for development costs related to a Phase 3 clinical trial of z","filed_date":"2023-11-02","accession":"0001178670-23-000023","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2023-11-02","accession":"0001178670-23-000023","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000023.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ated to the HELIOS-B Phase 3 clinical trial. In November 2021, Blackstone Life Sciences opted in to Phase 2 clinical trial funding of zilebesiran, committing to fund, upon meeting certain patient enrollment thresholds, up to $26.0million. Furthermore, Blackstone Life Sciences has the right, but is not obligated, to fund up to $54.0million for development costs related to a Phase 3 clinical trial of z","filed_date":"2023-08-03","accession":"0001178670-23-000015","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2023-08-03","accession":"0001178670-23-000015","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2023-05-04","accession":"0001178670-23-000011","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000011.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"to serve as a ClassI director for a term ending in 2026, or until a successor has been duly elected and qualified; | | |  |  |  2.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | |  |  |  3.To recommend, in a non-binding","filed_date":"2023-04-03","accession":"0001193125-23-089611","full_text":"https://origin.rootz.global/static/filing/0001193125-23-089611.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":22,"context":"ness of vaccination and booster vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business; our expectations regarding potential market","filed_date":"2023-02-23","accession":"0001178670-23-000005","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"resholds  44 [Table of Contents](#if18eecce00bf447982fe304ab60bdab5_7) are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on the timing or amount of those payments. Risks Related to Our Dependence on Third Parties We may not be able to execute our business strategy if we are unable to maintain existing or enter into new","filed_date":"2023-02-23","accession":"0001178670-23-000005","full_text":"https://origin.rootz.global/static/filing/0001178670-23-000005.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"ness of vaccination and booster vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business; our expectations regarding potential market","filed_date":"2022-10-27","accession":"0001178670-22-000026","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2022-10-27","accession":"0001178670-22-000026","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000026.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ness of vaccination and booster vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2022-07-28","accession":"0001178670-22-000020","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2022-07-28","accession":"0001178670-22-000020","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ness of vaccination and booster vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2022-04-28","accession":"0001178670-22-000016","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":31,"context":"lopment of any potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any of our commercially approved products, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2022-04-28","accession":"0001178670-22-000016","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"| | |  |  | | |  Nominating and Corporate Governance |  |  $7,500 | | |  |  | | |  Science and Technology |  |  $7,500 | | |  |  | | |  Initial Stock Option Award (vests ratably in three annual installments) |  |  $600,000 grant-date fair value** | | |  |  | | |  Annual Stock Option Award (vests on one-year anniversary)* |  |  $400,000 grant-date fair value** | | |  * |  Each non-employee director i","filed_date":"2022-04-05","accession":"0001193125-22-096188","full_text":"https://origin.rootz.global/static/filing/0001193125-22-096188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"Plan, to, among other things, increase the number of shares authorized for issuance thereunder by 6,000,000 shares; | | |  |  |  3.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | |  |  |  4.To ratify the appointment of P","filed_date":"2022-04-05","accession":"0001193125-22-096188","full_text":"https://origin.rootz.global/static/filing/0001193125-22-096188.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ness of vaccination and booster vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2022-02-10","accession":"0001178670-22-000013","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"portion of such future royalties and, if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on the timing or amount of those payments. Risks Related to Our Dependence on Third Parties We may not be able to execute our business strategy if we are unable to maintain existing or enter into new","filed_date":"2022-02-10","accession":"0001178670-22-000013","full_text":"https://origin.rootz.global/static/filing/0001178670-22-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"he necessity for and availability of booster vaccines, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2021-10-28","accession":"0001178670-21-000028","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"portion of such future royalties and, if certain specified thresholds are met, to the remaining portion of commercial milestone payments, and any negative developments related to Leqvio could have a material adverse effect on the timing or amount of those payments. Risks Related to Our Dependence on Third Parties We may not be able to execute our business strategy if we are unable to maintain existing or enter into new","filed_date":"2021-10-28","accession":"0001178670-21-000028","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"response, the effectiveness of vaccination campaigns, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2021-08-03","accession":"0001178670-21-000024","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":27,"context":"elated Risks Risks Related to Our Financial Results The current pandemic of the novel coronavirus, or COVID-19, and the future outbreak of other highly infectious or contagious diseases, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and pre-clinical studies. We are a young commercial company and the mark","filed_date":"2021-08-03","accession":"0001178670-21-000024","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000024.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"e broad availability of safe and effective vaccine(s), material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2021-04-29","accession":"0001178670-21-000017","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"elated Risks Risks Related to Our Financial Results The current pandemic of the novel coronavirus, or COVID-19, and the future outbreak of other highly infectious or contagious diseases, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and pre-clinical studies. We are an early-stage commercial company and t","filed_date":"2021-04-29","accession":"0001178670-21-000017","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000017.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"lam P5x25 Strategy to Deliver Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and Exceptional Financial Performance ** ** Provides Enrollment Update on HELIOS-B Phase 3 Study of Vutrisiran and Now Expects to Complete Enrollment in Late 2021, Ahead of Previous Expectations ** CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 29, 2021--Alnylam Pha","filed_date":"2021-04-29","accession":"0001157523-21-000536","full_text":"https://origin.rootz.global/static/filing/0001157523-21-000536.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"Corporate Governance |  |  $5,000 |  |  $7,500 | | |  |  |  | | |  Science and Technology |  |  $5,000 |  |  $7,500 | | |  |  |  | | |  Initial Stock Option Award (vests ratably in three annual installments) |  |  18,000 shares** |  |  $600,000 grant-date fair value** | | |  |  |  | | |  Annual Stock Option Award (vests on one-year anniversary)* |  |  9,000 shares** |  |  $400,000 grant-date fair va","filed_date":"2021-04-02","accession":"0001193125-21-105193","full_text":"https://origin.rootz.global/static/filing/0001193125-21-105193.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"o serve as a Class II director for a term ending in 2024, or until a successor has been duly elected and qualified; | | |  |  |  2.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the Compensation Discussion and Analysis, executive compensation tables and accompanying narrative disclosures in this proxy statement; | | |  |  |  3.To ratify the appointment of P","filed_date":"2021-04-02","accession":"0001193125-21-105193","full_text":"https://origin.rootz.global/static/filing/0001193125-21-105193.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"e broad availability of safe and effective vaccine(s), material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2021-02-11","accession":"0001178670-21-000010","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"elated Risks Risks Related to Our Financial Results The current pandemic of the novel coronavirus, or COVID-19, and the future outbreak of other highly infectious or contagious diseases, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and pre-clinical studies. We are an early-stage commercial company and t","filed_date":"2021-02-11","accession":"0001178670-21-000010","full_text":"https://origin.rootz.global/static/filing/0001178670-21-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ions and restrictive measures implemented in response, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2020-11-05","accession":"0001178670-20-000019","full_text":"https://origin.rootz.global/static/filing/0001178670-20-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"ny potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any approved product, including ONPATTRO and GIVLAARI, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2020-11-05","accession":"0001178670-20-000019","full_text":"https://origin.rootz.global/static/filing/0001178670-20-000019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ions and restrictive measures implemented in response, material delays in diagnoses of rare diseases, initiation or continuation of treatment for diseases addressed by our products, or in patient enrollment in clinical trials, potential clinical trial, regulatory review and inspection or supply chain disruptions, and other potential impacts to our business, the effectiveness or timeliness of steps ta","filed_date":"2020-08-06","accession":"0001178670-20-000015","full_text":"https://origin.rootz.global/static/filing/0001178670-20-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ALNY","company":"ALNYLAM PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":32,"context":"ny potential products or any approved product for an expanded indication in a timely manner or successfully launch, market and sell any approved product, including ONPATTRO and GIVLAARI, could have a material adverse effect on our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our research and development programs within the planned timeline,","filed_date":"2020-08-06","accession":"0001178670-20-000015","full_text":"https://origin.rootz.global/static/filing/0001178670-20-000015.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"0b33239aa8357e343573ac006ad887e1bfbbb2f33e3e685d01ce8835d5145663","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"bcb2f63efd5ca7fe790145c16dfb0fa695304c656514af33cccf24b3ac3a75de","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":75,"hourly_limit":500,"remaining":425,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}